Top Markets
#1 Nesa Nesa +795.86%
#2 Cortex Cortex +68.55%
#3 Merlin's Seal BTC Merlin's Seal BTC +45.65%
#4 QuantixAI QuantixAI +23.51%
#5 EXOD EXOD +22.78%
#6 Pons Pons +21.61%
#7 OpenEden OpenEden +17.10%
#8 Instadapp Instadapp +16.15%
#9 Magma Finance Magma Finance +12.82%
#10 Movement Movement +12.38%
Coin of the day
Nesa Nesa
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Molecular Partners AG Molecular Partners AG

Molecular Partners AG

MOLN
Pozycja w akcjach #19315
Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to... Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market novel therapeutic proteins. Leveraging its proprietary DARPin® platform, the company is advancing a diverse pipeline of product candidates. Key among these is Abicipar, a DARPin-based treatment currently in Phase III clinical development for significant ophthalmic conditions like neovascular wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Additionally, their portfolio features multi-specific DARPin candidates targeting infectious diseases, such as MP0420 and MP0423, both designed to combat the SARS-CoV-2 virus (COVID-19). In the oncology space, Molecular Partners is advancing several programs: MP0310, in Phase Ia for immuno-oncology; MP0317, a Phase I tumor-localized immune agonist engineered to activate immune cells within tumors; and MP0274, also in Phase I, aimed at HER2-positive cancers. Further early-stage assets include MP0533, a CD3 T cell candidate for acute myeloid leukemia, and MP0250, which targets vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and human serum albumin (HSA) to enhance therapeutic half-life. The company actively collaborates with leading pharmaceutical companies. Notable alliances include a partnership with Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; agreements with Amgen SA and Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc. They also maintain relationships with various other third-party collaborators. Established in 2004, Molecular Partners AG is headquartered in Schlieren, Switzerland.
Cena akcji
$4.43
Ostatnia synchronizacja: 2026-08-25
Kapitalizacja rynkowa
$166.36M
Zmiana (1 dzień)
-3.40%
Zmiana (1 rok)
21.63%
Kraj
CH
Handel Molecular Partners AG (MOLN)

Kategoria

Healthcare
Historia ceny akcji dla Molecular Partners AG (MOLN)
Najwyższa cena zamknięcia: $4.39 dnia 2026-08-01

Najniższa cena zamknięcia: $24.56 dnia 2015-03-01
Historia cen akcji firmy Molecular Partners AG od 2015 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2026 (TTM) -1.97%
2025 -21.29%
2024 23.60%
2023 -35.40%
2022 -60.06%
2021 -31.00%
2020 39.82%
2019 -1.96%
2018 -30.67%
2017 30.64%
2016 -40.17%
2015 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $553.09 42.85%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.02K 44.02%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $158.64 541.49%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.98 -12.73%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $772.27 7.33%
CH